Serial analysis of CTCs may provide biomarker predictive of NSCLC response to crizotinib

Serial analysis of CTCs may provide biomarker predictive of NSCLC response to crizotinib

http://bit.ly/2pN8f7U

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression-free survival.



Singularity

via http://bit.ly/2pNoqCk

April 30, 2017 at 04:25PM

Comments

Popular posts from this blog

How to capture videos of brains in real time

Kate McKinnon and Alec Baldwin break character to urge people to vote